Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBITDA Margin (2016 - 2025)

China Pharma Holdings' EBITDA Margin history spans 16 years, with the latest figure at 85.18% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 4070.0% year-over-year to 85.18%; the TTM value through Dec 2025 reached 70.57%, up 3694.0%, while the annual FY2025 figure was 70.57%, 3694.0% up from the prior year.
  • EBITDA Margin reached 85.18% in Q4 2025 per CPHI's latest filing, down from 78.57% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 13.81% in Q1 2023 to a low of 160.4% in Q2 2024.
  • Average EBITDA Margin over 5 years is 66.6%, with a median of 64.72% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: plummeted -7441bps in 2024, then surged 11087bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 28.97% in 2021, then decreased by -28bps to 37.0% in 2022, then plummeted by -39bps to 51.46% in 2023, then plummeted by -145bps to 125.87% in 2024, then soared by 32bps to 85.18% in 2025.
  • Per Business Quant, the three most recent readings for CPHI's EBITDA Margin are 85.18% (Q4 2025), 78.57% (Q3 2025), and 49.53% (Q2 2025).